ARTICLE | Financial News

FibroGen targeting near-billion dollar valuation

October 31, 2014 2:37 AM UTC

FibroGen Inc. (San Francisco, Calif.) set terms for its IPO on NASDAQ and plans to sell 7.1 million shares at $16-$19. At $17.50, the company would raise $124.3 million and be valued at $974.3 million. Goldman Sachs; Citigroup; Leerink Partners; RBC Capital Markets; Stifel, Nicolaus; and William Blair are underwriters.

Partner AstraZeneca plc (LSE:AZN; NYSE:AZN) plans to purchase $20 million of FibroGen stock in a concurrent private placement at the IPO price. ...